5th Fc-Mediated Function Summit

The landscape of Fc-mediated therapies is undergoing a radical transformation, driven by precise Fc-receptor targeting and antibody domain modification to unlock new levels of efficacy and safety for unprecedented therapeutic potential in oncology and autoimmune disease treatment. The 5th Fc-Mediated Function Summit is the essential destination for experts driving innovation in Fc-receptor targeting and antibody domain modification.

This year, we're evaluating the cutting-edge of Fc biology and engineering, diving deep into the game-changing potential of novel Fc modifications, bispecific formats, and targeted effector functions to revolutionize the treatment of cancer, autoimmune diseases, and beyond. Hear from the titans of the pharmaceutical industry, including AbbVie, Novartis, and UCB as well as innovative biotechs including Seismic Therapeutics, Paradigm Immunotherapies, and many more - as they share their groundbreaking research and strategies for developing more effective, safer, and long-lasting fc-mediated solutions. The therapeutic potential of Fc-mediated functions is surging following last year's wave in FDA approvals from BeiGene's Tevimbra to Genetech's approval of Piasky, and the pressure is on to continue this success and develop best-in-class treatments.

Don't miss this pivotal opportunity to network with 50+ leading scientists and drug development experts in the field of Fc-Mediated Function, forge crucial collaborations, and be part of the solution. The future of antibody therapeutics is being written now - be a part of it!

Speakers: Anne Altmeyer Chief Executive Officer TigaTx, Antoinette Russell Postdoctoral IU Fellow Boehringer Ingelheim, David Humphreys Executive Director and Head of Antibody and Novel Therapeutics UCB, Hayretin Yumerefendi Associate Director and Group Leader Novartis AG, Joel Cohen-Solal Principal Scientist Fc Biology Abbvie, Joel Heisler Postdoctoral Fellow, Antibody Engineering Genentech, Julian Chandler M.Sc. Associate Director, Discovery Research Alexion, AstraZeneca Rare Disease, Jyothsna Visweswaraiah Senior Director, Biotherapeutics, Drug Creation Seismic Therapeutic, Mark Chiu President Tavotek Biotherapeutics, Neil Bodie Chief Executive Officer Paradigm Immunotherapeutics Inc., Nidhi Jain Principal Scientist Synolo Therapeutics, Nimish Gera Co-founder and Vice- President of Biologics Mythic Therapeutics, Peter Sondermann Chief Executive Officer Tacalyx GmbH, Richard Blumberg Professor of Medicine Harvard University, Ryan Polli Senior Principal Scientist, PK Sciences Novartis AG, Sally Ward Director of Translational Immunology University of Southampton, Sreedhar Reddy Suthe Principal Scientist AstraZeneca, Vladimir Bobkov Principal Scientist Discovery Argenx